1.
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on card...
by Cannon, Christopher P., MD
The American heart journal, 2008, Vol.156 (5), p.826-832
2.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controll...
by Baigent, Colin, Prof
The Lancet (British edition), 2011, Vol.377 (9784), p.2181-2192
3.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
by Chataway, Jeremy, Dr
The Lancet (British edition), 2014, Vol.383 (9936), p.2213-2221
4.
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-con...
by Davidson, Michael H., MD
Clinical therapeutics, 2007, Vol.29 (7), p.1354-1367
5.
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet c...
by Bays, Harold E
Clinical therapeutics, 2004, Vol.26 (11), p.1758-1773
6.
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
by Armitage, Jane
The Lancet (British edition), 2010, Vol.376 (9753), p.1658-1669
7.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
by Jones, Peter H
The American journal of cardiology, 2003, Vol.92 (2), p.152-160
8.
Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress
by Alupei, Marius Costel
Cancer letters, 2014, Vol.356 (2), p.946-952
9.
Efficacy and Safety of Morning Versus Evening Dose of Controlled-Release Simvastatin Tablets in Patients With Hyperlipidemia: A Randomized, Double-Blind, Multicenter Phase III Tria...
by Kim, Sang-Hyun, MD, PhD
Clinical therapeutics, 2013, Vol.35 (9), p.1350-1360.e1
10.
Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway
by Gopalan, Archana
Cancer letters, 2012, Vol.329 (1), p.9-16
11.
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer
by Yin, Yefeng
Cancer letters, 2018-07-10, Vol.426, p.14-24
12.
Essential Role of MicroRNA-155 in Regulating Endothelium-Dependent Vasorelaxation by Targeting Endothelial Nitric Oxide Synthase
by Sun, Hai-Xiang
Hypertension (Dallas, Tex. 1979), 2012-12, Vol.60 (6), p.1407-1414
13.
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
by Canestaro, William J
Genetics in medicine, 2014-11, Vol.16 (11), p.810-819
14.
Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes
by Xu, Dan
Acta pharmacologica Sinica, 2014-09, Vol.35 (9), p.1215-1225
15.
Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase
by Maneechotesuwan, Kittipong, MD, PhD
Journal of allergy and clinical immunology, 2010, Vol.126 (4), p.754-762.e1
16.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
by Group, Heart Protection Study Collaborative
The Lancet (British edition), 2011, Vol.378 (9808), p.2013-2020
17.
On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
by Blazing, Michael A., MD
The American heart journal, 2016, Vol.182, p.89-96
18.
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
by Strandberg, Timo E
The Lancet (British edition), 2004-08-28, Vol.364 (9436), p.771-777
19.
Low Vitamin D as a Risk Factor for the Development of Myalgia in Patients Taking High-Dose Simvastatin: A Retrospective Review
by Mergenhagen, Kari, PharmD, BCPS AQ-ID
Clinical therapeutics, 2014, Vol.36 (5), p.770-777
20.
Statin Derivatives as Therapeutic Agents for Castration-Resistant Prostate Cancer
by Ingersoll, Matthew A
Cancer letters, 2016, Vol.383 (1), p.94-105
